TCM
AERI

Tradewinds Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Tradewinds Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-185
Closed -$11K – 739
2017
Q4 		$11K Hold
185
– – 0.01% 414
2017
Q3 		$9K Hold
185
– – ﹤0.01% 417
2017
Q2 		$10K Buy
+185
New +$8.61K 0.01% 399

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tradewinds Capital Management's AERI Position: Q1 2018 in Review

Tradewinds Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2018, closing a stake of 185 shares — an estimated $11K sold.

Tradewinds Capital Management first reported a position in AERI in Q2 2017 and held it in 3 quarters. The position peaked at $11K in Q4 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q1 2018.

  • Tradewinds Capital Management reported no remaining Aerie Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Tradewinds Capital Management sold 185 Aerie Pharmaceuticals shares in Q1 2018, an estimated $11K.
  • Tradewinds Capital Management first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Tradewinds Capital Management's Aerie Pharmaceuticals position peaked at $11K in Q4 2017.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2018.

Based on Tradewinds Capital Management's 13F filing for Q1 2018, filed 2 May 2018.